Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03293147
Other study ID # R120993
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 18, 2018
Est. completion date September 30, 2023

Study information

Verified date January 2024
Source University of Manchester
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Non-adherence to antihypertensive treatment is one of the leading causes of suboptimal blood pressure control and translates into increased risk of cardiovascular morbidity and mortality. Currently, there is no effective intervention for therapeutic non-adherence. Our project will assess whether high performance liquid chromatography mass spectrometry (HPLC-MS/MS)-guided intervention (providing patients with information on the results of their HPLC-MS/MS-based urine analysis combined with targeting the main reason for non-adherence) leads to an improvement in blood pressure control, adherence and a reduction in healthcare costs. Our multicentre prospective randomised controlled trial consists of 6 stages (screening, recruitment, baseline phenotype assessment, intervention, short-term and long-term outcome visits). The study will fill in an important gap in knowledge on management of blood pressure in non-adherent hypertensive patients beyond the initial diagnostic step. It will also inform the development of a cost-effective model for the management of non-adherence in chronic disorders that require long-term drug therapy.


Description:

Non-adherence to antihypertensive treatment is one of the leading causes of suboptimal blood pressure control and translates into increased risk of cardiovascular morbidity and mortality. Currently, there is no effective intervention for therapeutic non-adherence. An ultra-sensitive and highly specific biochemical assay has been developed to detect urinary biomarkers of antihypertensive treatment. The high performance liquid chromatography mass spectrometry (HPLC-MS/MS)-based assay screens spot urine samples for the presence of 40 commonly prescribed blood pressure lowering medications. The results of the test provide a clinician with information on the presence/absence of prescribed antihypertensive drugs or/and their metabolites in urine - a direct confirmation of therapeutic adherence/non-adherence. The study is a prospective multi-centre randomised controlled trial to examine if HPLC-MS/MS-guided intervention is superior to standard clinical care in improving clinical, behavioural and health-economy outcomes in hypertensive patients who are non-adherent to antihypertensive treatment. Patient adherence to antihypertensive treatment will be determined at baseline. Non-adherent hypertensive patients at baseline will be randomised in a 1:1 ration to either usual clinical care plus HPLC-MS/MS-guided intervention (Arm A) or usual clinical care only (Arm B). The study also evaluates a cohort of patients who are adherent to antihypertensive treatment at baseline. Those adherent hypertensive patients will receive the usual clinical care (Arm C). The main purpose of involving this group of patients is to blind the clinical research staff to the adherence status of those patients randomised receiving standard care alone, to prevent introducing any bias in treating non-adherent patients.


Recruitment information / eligibility

Status Completed
Enrollment 200
Est. completion date September 30, 2023
Est. primary completion date August 4, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male or female aged 18 years or above - Patients previously diagnosed with and pharmacologically managed for hypertension - Patients with antihypertensive treatment with at least two antihypertensive medications - Patients have full capability of providing informed consent Exclusion Criteria: - Patients with recent history of admission to the hospital relating to their hypertension or treatment with anti-hypertensive medications (<2 weeks) (i) - Patient refusal for 7-day home-based blood pressure monitoring (7-HBBPM) - Self-reported pregnancy or breastfeeding - Female patients planning to conceive within the next 6 months (i) Including admission to A&E

Study Design


Related Conditions & MeSH terms


Intervention

Other:
HPLC-MS/MS-guided intervention
The HPLC-MS/MS-guided intervention consists of providing partially or totally non-adherent hypertensive patients with information on the results of their HPLC-MS/MS-based urine analysis combined with tailored targeting of the main reason(s) for the deviation from the prescribed antihypertensive treatment
Standard care
Standard care for hypertensive patients

Locations

Country Name City State
United Kingdom Alvaston Medical Centre Derby
United Kingdom Ninewells Hospital Dundee Scotland
United Kingdom Epsom & St. Helier University Hospitals NHS Trust Epsom
United Kingdom Glenfield General Hospital Leicester
United Kingdom Guy's and St Thomas' Hospital London
United Kingdom Homerton Hospital London
United Kingdom Royal Free Hospital London
United Kingdom St Bartholomews Hospital London
United Kingdom University College London Hospitals NHS Foundation Trust London Greater London
United Kingdom Manchester Royal Infirmary Manchester Greater Manchester
United Kingdom Chilwell Valley and Meadows Practice Nottingham
United Kingdom University Hospitals Dorset NHS Foundation Trust Poole

Sponsors (4)

Lead Sponsor Collaborator
University of Manchester British Heart Foundation, Manchester Academic Health Science Centre, Omron Healthcare Co., Ltd.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Changes in psychological profile Psychological questionnaires assessing participants perspectives of treatment will be completed by patient when attending clinic visit 1, 4 and 5 visit 4 (short term follow-up; ~3 months post intervention, when feasible to conduct)
Other Changes in psychological profile Psychological questionnaires assessing participants perspectives of treatment will be completed by patient when attending clinic visit 1, 4 and 5 visit 5 (long term follow-up; ~4.5 months post intervention, when feasible to conduct)
Primary Change in Clinic systolic blood pressure Blood pressure measurements will be taken after 5 minutes of rest in a sitting position with an electronic digital Omron monitor and the cuff size adjusted to the arm circumference as per international guidelines. Three measurements of systolic blood pressure will be taken in a row (separated by approximately 1 minute interval) and recorded at every visit visit 4 (short term follow-up; approx. 3 months post intervention, when feasible to conduct)
Secondary Change in clinic systolic blood pressure Blood pressure measurements will be taken after 5 minutes of rest in a sitting position with an electronic digital Omron monitor and the cuff size adjusted to the arm circumference as per international guidelines. Three measurements of systolic blood pressure will be taken in a row (separated by approximately 1 minute interval) and recorded at every visit visit 5 (long term follow-up; ~4.5 months post intervention, when feasible to conduct)
Secondary Change in clinic diastolic blood pressure Blood pressure measurements will be taken after 5 minutes of rest in a sitting position with an electronic digital Omron monitor and the cuff size adjusted to the arm circumference as per international guidelines. Three measurements of diastolic blood pressure will be taken in a row (separated by approximately 1 minute interval) and recorded at every visit visit 4 (short term follow-up; ~3 months post intervention, when feasible to conduct)
Secondary Change in clinic diastolic blood pressure Blood pressure measurements will be taken after 5 minutes of rest in a sitting position with an electronic digital Omron monitor and the cuff size adjusted to the arm circumference as per international guidelines. Three measurements of diastolic blood pressure will be taken in a row (separated by approximately 1 minute interval) and recorded at every visit visit 5 (long term follow-up; ~4.5 months post intervention, when feasible to conduct)
Secondary Change in home blood pressure This measurement will be conducted using oscillometric Omron monitors. Patients will be handed the monitors by the research nurses at each visit and will be provided instructions to use the Omron monitor. While all blood pressure measurements will be stored automatically on the monitors, patients will be also asked to keep a written record on paper (to avoid loss of data in case a monitor stops working or goes out of order). visit 4 (short term follow-up; ~3 months post intervention, when feasible to conduct)
Secondary Change in home blood pressure This measurement will be conducted using oscillometric Omron monitors. Patients will be handed the monitors by the research nurses at each visit and will be provided instructions to use the Omron monitor. While all blood pressure measurements will be stored automatically on the monitors, patients will be also asked to keep a written record on paper (to avoid loss of data in case a monitor stops working or goes out of order). visit 5 (long term follow-up; ~4.5 months post intervention, when feasible to conduct)
Secondary Change in biochemical adherence of patients HPLC-MS/MS test will determine the numbers and list of antihypertensive drugs detected in the patient urine sample and this will be compared to the patient prescription visit 2 (~3 weeks post recruitment, when feasible to conduct)
Secondary Change in biochemical adherence of patients HPLC-MS/MS test will determine the numbers and list of antihypertensive drugs detected in the patient urine sample and this will be compared to the patient prescription. visit 4 (short term follow-up; ~3 months post intervention, when feasible to conduct)
Secondary Change in biochemical adherence of patients HPLC-MS/MS test will determine the numbers and list of antihypertensive drugs detected in the patient urine sample and this will be compared to the patient prescription. visit 5 (long term follow-up; ~4.5 months post intervention, when feasible to conduct)
Secondary Change in urinary albumin / creatinine ratio Urinary albumin / creatinine ratio is a urinary marker of target organ damage. visit 4 (short term follow-up; ~3 months post intervention, when feasible to conduct)
Secondary Change in urinary albumin / creatinine ratio Urinary albumin / creatinine ratio is a urinary marker of target organ damage. visit 5 (long term follow-up; ~4.5 months post intervention, when feasible to conduct)
Secondary Changes in health economy parameters Health economy parameters (collected via questionnaires) will be calculated over the study time horizon to determine total costs of clinical/social care visit 4 (short term follow-up; ~3 months post intervention, when feasible to conduct)
Secondary Changes in health economy parameters Health economy parameters (collected via questionnaires) will be calculated over the study time horizon to determine total costs of clinical/social care visit 5 (long term follow-up; ~4.5 months post intervention, when feasible to conduct)
See also
  Status Clinical Trial Phase
Terminated NCT04591808 - Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia Phase 3
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Completed NCT03093532 - A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT05529147 - The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
Recruiting NCT05976230 - Special Drug Use Surveillance of Entresto Tablets (Hypertension)
Completed NCT06008015 - A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers Phase 1
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Recruiting NCT05121337 - Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension N/A
Withdrawn NCT04922424 - Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men Phase 1
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Not yet recruiting NCT05038774 - Educational Intervention for Hypertension Management N/A
Completed NCT05087290 - LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
Completed NCT05621694 - Exploring Oxytocin Response to Meditative Movement N/A
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Recruiting NCT05575453 - OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure N/A
Completed NCT03875768 - Nourish: A Digital Health Program to Promote the DASH Eating Plan Among Adults With High Blood Pressure N/A